NasdaqGS:REGNBiotechs
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Q4 2025 Beat And New EYLEA HD Data
Regeneron Pharmaceuticals (REGN) has just paired a Q4 2025 earnings beat with fresh momentum in its eye franchise, as new EYLEA HD data head to the Angiogenesis meeting and recent approvals broaden treatment options.
See our latest analysis for Regeneron Pharmaceuticals.
Those Q4 beats and fresh EYLEA HD data come after a 17.85% 90 day share price return and a 9.52% one year total shareholder return, hinting that momentum has picked up recently despite softer near term moves.
If Regeneron’s...